Ioannis Vathiotis

Physician scientist | Medical Oncologist @uoaofficial Sotiria Hospital, Research Affiliate @YaleMed | Interested in #lungcancer #immunotherapy #biomarkers

[Ioannis Vathiotis @IVathiotis]

Lung cancer is, in part, a hereditary disease. Excited to share our perspective on the incorporation of germline testing in patients with lung cancer @triparnasen @fred_hirsch @SyrigosKostas @elekapLC @LancetRespirMed https://t.co/4AaijEnXPV.

[Balazs Halmos @BalazsHalmosMD]

Tam-peli or Riz-rez?
(Sound like popular K-pop singers…)

Or Idxd?

Seems like a long line-up of promising B7H3 (identical amazing OS HR=0.46 for both vs topotecan!) targeting ADCs ready to take on the 2nd line space which starlatamab is about to void.

Now which one will remain standing?
1st to market?
CNS?
Less ILD?

The Squid games of B7H3 ADCs is about to begin… good old topotecan seems at this point first out..

[Prof Tom John @TommyJohn00]

Practice changing #SWOG S18 MAVERICK trial by C Rusthoven. I think this should be seen as then end of using PCI in SCLC. Endpoints changed bc slow recruitment. Although more CNS mets pfs was the same. Less toxicity, which increases over time. Not a surprise, but well conducted.

[Yale Pathology @yalepathology]

Congratulations to David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and Professor of Medicine (Medical Oncology) @YaleMed, on being selected by the @AACR for its 2026 James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research. https://t.co/nGozKhipra

[Hellenic Association of Lung Cancer (HeALC) ΕΛΕΚΑΠ @elekapLC]

Το ΣΟΚ της διάγνωσης — η στιγμή που όλα αλλάζουν.
Το 2ο τεύχος του «ΠΝΟΕΣ» μόλις κυκλοφόρησε!

Διαβάστε το τεύχος → https://t.co/ot5t1egXL6

#Pnoes #Elekap #TogetherWeCan #PnoesMagazine #Oncology #healthandlifestylemagazine

[Kostas Syrigos @SyrigosKostas]

🫁 PNOES, the new magazine by ELEKAP, is here — a space where science meets empathy, and stories of strength and healing inspire us all to breathe, connect and live better.

Discover the first issue : https://t.co/4h1tGsKN4L
#PNOESMagazine

[Yale Pathology @yalepathology]

There’s nothing like Cedar Street in the fall. @YaleMed

[Arutha K @aruthak]

Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer @NatureGenet @OncoAlert #SpatialMedicine #lungcancer #PrecisionMedicine https://t.co/Bg5W7f1jf3

[Cancer Discovery @CD_AACR]

Mini Review: Histologic Transformation in Cancer: The Path for Clinical Translation https://t.co/yak0B5diV6
By @IVathiotis, @AvisekBanerje11, @triparnasen, and colleagues at @OhioStateMedOnc @IcahnMountSinai @uoaofficial

[Jarushka Naidoo @DrJNaidoo]

#WCLC25 Presidential
FLAURA2 OS in 1L EGFR+ NSCLC:

- mOS 47.5m v 37.6m (HR 0.77 p=0.02)
- duration of osi 30.5m on osi+chemo v 21.2m osi- combo delays acq resistance? - 72% got 2L chemo- does this add ~9m?
- all subgrps benefit (?BM, ?co-mtns)

Congrats @dplanchard @iaslc #LCSM

[Jordi Remon @JordiRemon]

FLAURA2 trial: Osi + CT improves PFS & OS (⬇️ 23% risk death) vs Osi alone in mEGFR NSCLC. Qx:
-Intensification for all pts? Benefit in some subgroups only (Brain)
-Chemo or ami for intensification?toxicity QoL, relevant for decisions
-Cost
-Is Osi alone no more valid?
#WCLC2025

[Triparna Sen (Sen-Lab) @triparnasen]

🧵(1/3)

Thrilled to share our timely review just published in @CD_AACR: Histologic Transformation in #Cancer: The Path for Clinical Translation.

This complex and dynamic adaptive process poses major #clinical #challenges in #lungcancer and #prostatecancer.

#CellPlasticity #DrugResistance #CancerResearch
#LCSM #LUAD #SCLC #LUSC #NEPC #PDAC @oncodaily @OncLive @OncoAlert @OSUWexMed @OhioStateMedOnc @OhioState @OhioStateWIMS @LUNGevity @lcrf_org @lcfamerica @LiveLung1 @IASLC @PCR_News @AACR @ElizSMcKenna

[Triparna Sen (Sen-Lab) @triparnasen]

Excited to share our review on "Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity" in @JTOonline.

We examine how #LUAD transforms into #SCLC or #LUSC under treatment pressure as a key factor in #resistance, and unpack the #genetic, #epigenetic, and #immune programs that drive this #evolution.

Understanding these histologic switches opens the way for new #therapeutictargets to prevent or stop tumor escape.

So proud to have collaborated with an amazing and fun team of friends and collaborators- @AvisekBanerje11, @IVathiotis, @fred_hirsch, @SyrigosKostas, @drshieldsmd, @UtsavSen10, Drs. Raj Veluswamy, Xuejun Wang, Debdatta Halder.

@IcahnMountSinai @OSUCCC_James @IASLC @Pelotonia @OncLive @oncodaily @LiveLung1 @lcrf_org @LUNGevity @SclcSMASHERS @lcfamerica #SCLC #NSCLC #lungcancer #translationalresearch #CancerResearch #lineageplasticity #onegoal #EndingCancer

https://t.co/TOFgMj6FF8

[Fred R. Hirsch @fred_hirsch]

Great publication paving the way into the future! Proud to be co-author! Congrats to Dr. Sen the group! Just published in JTO.

[NEJM @NEJM]

Presented at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz

@ASCO

[Ioannis Vathiotis @IVathiotis]

@triparnasen is an excellent candidate for the @IASLC Board of Directors (Basic Science). She has all the qualities and demeanour to make the difference. She is a driven scientist and great collaborator!

[Triparna Sen (Sen-Lab) @triparnasen]

I am truly thrilled and humbled to be nominated as a candidate for the @IASLC Board of Directors (Basic Science). @IASLC has been my professional home for nearly a decade—a place that has shaped my journey as a #scientist, #mentor, and #collaborator. I have met some of the most inspiring scientists and mentors through @IASLC.

To be considered for this role is both a personal milestone and a profound opportunity to give back to the global #lungcancer community.

With deep gratitude to those who have supported my path (@fred_hirsch @JhanelleGray), I am committed to advancing IASLC's mission to advance #lungcancer #research, #education, and #multidisciplinary partnerships.
I am passionate about and will work towards:
🔬 Elevating basic and translational science
🌱 Empowering the next generation of investigators
🤝 Strengthening global collaborations
📚 Expanding access to education and mentorship
💡 Building new bridges for funding and innovation

Voting is open April 17 – May 22 for all IASLC members. Look out for a personalized ballot from: [email protected]

🔗 Learn more about Basic Science Candidates (including me): https://t.co/UtTiuNmPy2
Let us shape the future of lung cancer care together 💙.

#IASLC #LungCancerResearch #TranslationalScience #GlobalOncology #Leadership #ThoracicOncology #IASLC2025 #LCSM
@IcahnMountSinai @TischCancer @lcfamerica @lcrf_org @LUNGevity @LiveLung1 @oncodaily @lcsmchat

[Triparna Sen (Sen-Lab) @triparnasen]

I am truly thrilled and humbled to be nominated as a candidate for the @IASLC Board of Directors (Basic Science). @IASLC has been my professional home for nearly a decade—a place that has shaped my journey as a #scientist, #mentor, and #collaborator. I have met some of the most inspiring scientists and mentors through @IASLC.

To be considered for this role is both a personal milestone and a profound opportunity to give back to the global #lungcancer community.

With deep gratitude to those who have supported my path (@fred_hirsch @JhanelleGray), I am committed to advancing IASLC's mission to advance #lungcancer #research, #education, and #multidisciplinary partnerships.
I am passionate about and will work towards:
🔬 Elevating basic and translational science
🌱 Empowering the next generation of investigators
🤝 Strengthening global collaborations
📚 Expanding access to education and mentorship
💡 Building new bridges for funding and innovation

Voting is open April 17 – May 22 for all IASLC members. Look out for a personalized ballot from: [email protected]

🔗 Learn more about Basic Science Candidates (including me): https://t.co/UtTiuNmPy2
Let us shape the future of lung cancer care together 💙.

#IASLC #LungCancerResearch #TranslationalScience #GlobalOncology #Leadership #ThoracicOncology #IASLC2025 #LCSM
@IcahnMountSinai @TischCancer @lcfamerica @lcrf_org @LUNGevity @LiveLung1 @oncodaily @lcsmchat

[Noemi Reguart @NReguart]

Phase I/II SOHO-01: BAY 2927088 in HER2m NSCLC. In HER2i-naive (cohort D): ORR 70.5%, DoR 8.7 mo. EGFRi-like AEs (rash, diarrhea). Busy Ph3 landscape: TKIS (SOHO-02, WU-KONG28 FURMO-004) or TKIs + ChT (REZILIENT3) vs SoC in 1L HER2m NSCLC #ESMOAmbassadors #ELCC25 @myESMO

[Yale Pathology @yalepathology]

New test developed for #breastcancer by @RimmPathology at @YaleMed may allow for more personalized #lungcancer therapy. “The way we did this measurement was by using cell line standards, which is a bit novel,” Dr. Rimm tells @HemOncToday. @YaleCancer https://t.co/ErDVZxjWW7

[Stephen V Liu, MD @StephenVLiu]

Retrospective report in European Journal of Cancer on #EGFR mutant NSCLC transformed to #SCLC. Post transformation, 93% were DLL3 positive. Are BiTEs like tarlatamab viable options here? No clear current standard (chemo, chemo + TKI, chemo + IO).

https://t.co/Eh0GjqISlO

[Giannis Mountzios @g_mountzios]

Another proof of concept that adjuvant component of perioperative IO is NOT for all: NOT adding benefit to patients who achieve PCR and NOT enough for patients without MPR/PCR…Room for deescalation for PCR patients and for escalation strategies in non-PCR/ MPR?? Congrats @RobertoFerrara_ and all authors for this insight, one thing is for sure, perioperative IO will not be as we know today in one year from now
#some #lcsm @OncoAlert @OncoViews @OncBrothers @VJOncology @HeSMO_X